



PAGE:
06/06/2002

17:40:08

VERIFICATION SUMMARY REPORT

PATENT APPLICATION

DATE:

TIME:

INPUT SEQ: A:\1962-4050US1.txt

GENERAL INFORMATION SECTION

3,<110> Bay, Sylvie
4, Cantacuzene, Daniele
5, Leclerc, Claude
6, Lo-Man, Richard
8,<120> MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE,
9, VACCINE COMPRISING THE SAME AND USE THEREOF
11,<130> 102.166A-1
13,<140> 09/405,986
14,<141> 1999-09-27
16,<150> US 09/049,847
17,<151> 1998-03-27
19,<150> US 60/041,726
20,<151> 1997-03-27
22,<160> 25
24,<170> PatentIn version 3.1

ERRORED LINES SECTION

W--> 115 Xaa Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Xaa

STATISTICS SUMMARY

Application Serial Number: 09/405,986
Alpha or Numeric: Numeric
Application Class:
Application File Date: 1999-09-27
Art Unit:
Software Application: PatentIN3.1
Total Number of Sequences: 25
Total Nucleotides: 0
Total Amino Acids: 348
Number of Errors: 0
Number of Warnings: 1
Number of Corrections: 0

RECEIVED
JUL 17 2002
TECH CENTER 1600/2900



SEQUENCE LISTING

<110> Bay, Sylvie
Cantacuzene, Daniele
Leclerc, Claude
Lo-Man, Richard

<120> MULTIPLE ANTRIGEN GLYCOPEPTIDE CARBOHYDRATE,
VACCINE COMPRISING THE SAME AND USE THEREOF

<130> 102.166A.

<140> 09/405,986
<141> 1999-09-27

<150> US 09/049,847
<151> 1998-03-27

<150> US 60/041,726
<151> 1997-03-27

<160> 25

<170> PatentIn version 3.1

<210> 1
<211> 15
<212> PRT
<213> Clostridium tetani

<400> 1

Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
1 5 .10 15

<210> 2
<211> 21
<212> PRT
<213> Clostridium tetani

<400> 2

Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
1 5 .10 15

Ala Ser His Leu Glu
20

<210> 3
<211> 12
<212> PRT
<213> Clostridium tetani

<400> 3

Gly Gln Ile Gly Asn Asp Pro Asn Arg Asp Ile Leu
1 5 .10

<210> 4
<211> 13
<212> PRT

<213> Poliovirus

<400> 4

Lys Leu Phe Ala Val Trp Lys Ile Thr Tyr Lys Asp Thr
1 5 10

<210> 5

<211> 15

<212> PRT

<213> Escherichia coli

<400> 5

Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser
1 5 10 15

<210> 6

<211> 13

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Designed peptidic T-Helper Cell epitope that typically binds to a plurality of human and murine Major Histocompatibility Complex Class II molecules

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa=D-Ala

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=L-cyclohexyl-Ala

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> Xaa=D-Ala

<400> 6

Xaa Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Xaa
1 5 10

<210> 7

<211> 10

<212> PRT

<213> Human papillomavirus type 16

<220>

<221> MISC_FEATURE

<223> HPV16 E7 PEPTIDE

<400> 7

Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn
1 5 10

<210> 8
<211> 10
<212> PRT
<213> Human papillomavirus type 16

<220>
<221> MISC_FEATURE
<223> HPV16 E7 PEPTIDE

<400> 8

Ala Glu Pro Asp Arg Ala His Tyr Asn Ile
1 5 10

<210> 9
<211> 19
<212> PRT
<213> Human papillomavirus type 16

<220>
<221> MISC_FEATURE
<223> HPV 16 E7 PEPTIDE

<400> 9

Lys Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val Ile
1 5 10 15

Arg Thr Leu

<210> 10
<211> 10
<212> PRT
<213> Human papillomavirus type 16

<220>
<221> MISC_FEATURE
<223> HPV16 E7 PEPTIDE

<400> 10

Gly Thr Leu Gly Ile Val Cys Pro Ile Cys
1 5 10

<210> 11
<211> 13
<212> PRT
<213> Homo sapiens

<400> 11

Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser
1 5 10

<210> 12
<211> 15
<212> PRT
<213> Homo sapiens

<400> 12

His Leu Asp Met Leu Arg His Leu Tyr Gln Gly Cys Gln Val Val
1 5 10 15

<210> 13
<211> 15
<212> PRT
<213> Homo sapiens

<400> 13

Ser Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val
1 5 10 15

<210> 14
<211> 14
<212> PRT
<213> Homo sapiens

<400> 14

Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val Thr Lys Ala Glu
1 5 10

<210> 15
<211> 10
<212> PRT
<213> POLIOVIRUS

<400> 15

Phe Ala Val Trp Lys Ile Thr Tyr Lys Asp
1 5 10

<210> 16
<211> 14
<212> PRT
<213> Clostridium tetani

<400> 16

Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
1 5 10

<210> 17
<211> 11
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>

<223> Designed synthetic linear glycopeptide containing a saccharidic
B-cell epitope and a CD4+ T-cell epitope able to induce anti-

saccharidic antibodies

<400> 17

Ser Thr Thr Gly Gly Gly Gly Gly Lys Gly
1 5 10

<210> 18

<211> 11

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Designed synthetic linear glycopeptide containing a saccharidic B-cell epitope and a CD4+ T-cell epitope able to induce anti-saccharidic antibodies

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> alpha-N-acetylgalactosamine (GalNAc)-Serine

<220>

<221> MISC_FEATURE

<222> (2)..(3)

<223> alpha-N-acetylgalactosamine (GalNAc)-Threonine

<400> 18

Ser Thr Thr Gly Gly Gly Gly Gly Lys Gly
1 5 10

<210> 19

<211> 11

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Designed synthetic linear glycopeptide containing a saccharidic B-cell epitope and a CD4+ T-cell epitope able to induce anti-saccharidic antibodies

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> alpha-N-acetylgalactosamine (GalNAc)-Serine

<220>

<221> MISC_FEATURE

<222> (2)..(3)

<223> alpha-N-acetylgalactosamine (GalNAc)-Threonine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Biotinylated

<400> 19

Ser Thr Thr Gly Gly Gly Gly Gly Lys Gly
1 5 10

<210> 20

<211> 11

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Designed synthetic linear glycopeptide containing a saccharidic B-cell epitope and a CD4+ T-cell epitope able to induce anti-saccharidic antibodies

<220>

<221> MISC_FEATURE

<222> (7)..(8)

<223> alpha-N-acetylgalactosamine (GalNAc)-Threonine

<400> 20

Lys Gly Gly Gly Ser Thr Thr Gly Gly Gly
1 5 10

<210> 21.

<211> 14

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Designed synthetic linear glycopeptide containing a saccharidic B-cell epitope and a CD4+ T-cell epitope able to induce anti-saccharidic antibodies

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> alpha-N-acetylgalactosamine (GalNAc)-Serine

<400> 21

Ser Lys Leu Phe Ala Val Trp Lys Ile Thr Tyr Lys Asp Thr
1 5 10

<210> 22

<211> 16

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<223> Designed synthetic linear glycopeptide containing a saccharidic B-cell epitope and a CD4+ T-cell epitope able to induce anti-saccharidic antibodies

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> alpha-N-acetylgalactosamine (GalNAc)-Serine

<220>
<221> MISC_FEATURE
<222> (2)..(3)
· <223> alpha-N-acetylgalactosamine (GalNAc)-Threonine

<400> 22

Ser Thr Thr Lys Leu Phe Ala Val Trp Lys Ile Thr Tyr Lys Asp Thr
1 5 10 15

<210> 23
<211> 16
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Designed synthetic linear glycopeptide containing a saccharidic
B-cell epitope and a CD4+ T-cell epitope able to induce anti-
saccharidic antibodies

<220>
<221> MISC_FEATURE
<222> (1)..(3)
· <223> alpha-N-acetylgalactosamine (GalNAc)-D-Serine

<400> 23

Ser Ser Ser Lys Leu Phe Ala Val Trp Lys Ile Thr Tyr Lys Asp Thr
1 5 10 15

<210> 24
<211> 22
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Designed synthetic linear glycopeptide containing a saccharidic
B-cell epitope and a CD4+ T-cell epitope able to induce anti-
saccharidic antibodies

<220>
<221> MISC_FEATURE
<222> (1)..(1)
· <223> alpha-N-acetylgalactosamine (GalNAc)-Serine

<220>
<221> MISC_FEATURE
<222> (2)..(3)
· <223> alpha-N-acetylgalactosamine (GalNAc)-Threonine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
· <223> alpha-N-acetylgalactosamine (GalNAc)-Glycine

<220>
<221> MISC_FEATURE
<222> (5)..(5)

<223> alpha-N-acetylgalactosamine (GalNAc)-Serine

<220>
<221> MISC_FEATURE
<222> (6)..(7)
<223> alpha-N-acetylgalactosamine (GalNAc)-Threonine

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> alpha-N-acetylgalactosamine (GalNAc)-Glycine

<400> 24

Ser Thr Thr Gly Ser Thr Thr Gly Lys Leu Phe Ala Val Trp Lys Phe
1 5 10 15

Ile Thr Tyr Lys Asp Thr
20

<210> 25
<211> 17
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<223> Designed synthetic linear glycopeptide containing a saccharidic
B-cell epitope and a CD4+ T-cell epitope able to induce anti-
saccharidic antibodies

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> alpha-N-acetylgalactosamine (GalNAc)-Serine

<220>
<221> MISC_FEATURE
<222> (2)...(3)
<223> alpha-N-acetylgalactosamine (GalNAc)-Threonine

<400> 25

Ser Thr Thr Gln Tyr Ile Lys Ala Asn Ser Lys Ile Gly Ile Thr Glu
1 5 10 15

Leu